Stock Analysis
Replimune Group, Inc. (REPL) Stock Analysis
Replimune Group, Inc. (REPL) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Replimune Group, Inc. (REPL) currently has an AIQ Score of 60/100, indicating a neutral setup. Momentum is the strongest factor at 97/100. Risk is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
REPL at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $21.89 |
| AIQ Score | 60/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $2.3B |
| P/E Ratio (TTM) | -7.85 |
| Forward P/E | — |
| EPS (Q2 FY2027) | -$0.54 |
| Revenue (Q2 FY2027) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.9 |
| Volume | 2.02M |
| 52-week range | $1.50-$23.54 |
| RSI 14 | 72.07 |
| 50-Day SMA | $14.76 |
| 200-Day SMA | $10.00 |
| Analyst Price Target | $30.00 |
| Next Earnings | Feb 2, 2027 |
REPLReplimune Group, Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Sector Leader
Latest quote
- Momentum97
- Value—
- Quality35
- Risk resilience26
- Sentiment—
REPL Stock Analysis Summary
Replimune Group, Inc. (REPL) currently has an AIQ Score of 60/100, indicating a neutral setup. Momentum is the strongest factor at 97/100. Risk resilience is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, REPL has AIQ Score of 60/100 with Momentum base of 97/100 and fading Risk resilience at 26/100. Wait for component alignment before adding exposure.
Momentum (97/100) leads while Risk resilience (26/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.41% stock move · REPL classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is REPL Bullish or Bearish Right Now?
REPL currently has a neutral overall setup. Momentum is the strongest factor at 97/100, while Risk Resilience is weakest at 26/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 97/100.
- - Price is +48.27% above its 50-day SMA.
- - Analyst target implies +37.05% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (36 vs 7).
- - Risk Resilience is weak at 26/100.
Current Consensus
REPL's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 3 neutral, and 7 sell votes. REPL's 14-day RSI is 72.07, which places the stock in an overbought momentum range. REPL's beta is 0.9, indicating market sensitivity broadly in line with the market.
What Changed in REPL?
The largest recent change in REPL is AIQ Score moving up by 1.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the REPL Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
REPL Decision Framework
Public evidence layers, setup checks, and risk context for Replimune Group, Inc..
Replimune Group, Inc. (REPL) Stock Analysis
Replimune Group, Inc. has an AIQ Score of 60/100 in a Neutral regime. Momentum is strongest at 97/100. Beta is 0.9, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | REPL is in a Neutral AIQ regime with score 60/100. |
| Signal Conflict | The primary conflict is that momentum leads at 97/100 while risk lags at 26/100. |
| Factor Evidence | Momentum 97/100 · Quality 35/100 · Risk 26/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 97/100.
Momentum is 97/100 and RSI (14) is 72.1.
REPL is in a Neutral regime at 60/100.
Risk factor is 26/100 with beta 0.9 and annual volatility 187.93%.
Current conflict: momentum leads at 97/100 while risk lags at 26/100.
REPL Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
REPL Fundamentals
REPL valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
REPL Technical Analysis
REPL technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
REPL Stock Catalysts
Track REPL earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
REPL Dividend Analysis
REPL dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
REPL Financial Data
REPL revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
REPL Risk Analysis
REPL volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
REPL Stock News
REPL stock news, market tone, recent headlines, and catalyst context.
REPL vs Biotechnology Peers
Current peer cohort: REPL · RLAY · RVMD · RYTM · SEPN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| REPL Current stock | 60/100 | — | 97/100 | 26/100 | 1.3 | 187.93% | Current |
| RLAY Relay Therapeutics, Inc. | 56/100 | 37/100 | 76/100 | 52/100 | 1.84 | 65.80% | REPL vs RLAY |
| RVMD Revolution Medicines, Inc. | 55/100 | 39/100 | 73/100 | 59/100 | 1.69 | 68.69% | REPL vs RVMD |
| RYTM Rhythm Pharmaceuticals, Inc. | 62/100 | 52/100 | 72/100 | 57/100 | 0.52 | 54.57% | REPL vs RYTM |
| SEPN Septerna Inc | 69/100 | 55/100 | 87/100 | 52/100 | 1.43 | 69.35% | REPL vs SEPN |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for REPL: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching REPL
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for REPL
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
REPL Stock FAQ
What is REPL stock price today?
Replimune Group, Inc.'s current stock price is $21.89. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is REPL bullish or bearish right now?
REPL's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is REPL's market cap?
REPL's market cap is $2.3B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is REPL's current P/E ratio?
REPL's current P/E ratio is -7.85 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is REPL's RSI?
REPL's 14-day RSI is 72.07 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is REPL above its 50-day and 200-day moving averages?
REPL is 48.27% from its 50-day SMA and 118.86% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is REPL's next earnings date?
REPL's next earnings date is currently listed as Feb 2, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does REPL pay a dividend?
REPL's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.